Synthesis and characterization of the amyloid β40 dimer model with a linker at position 30 adjacent to the

Kazuma Murakami1, Takashi Suzuki1, Mizuho Hanaki1

  • 1Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan.

Insights

Amyloid beta-40 (Aβ40) dimers with specific structures may not cause Alzheimer's disease (AD) pathology. Modified Aβ40 dimers forming stable oligomers, rather than fibrils, showed no neurotoxicity in this study.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Amyloid fibrils, primarily Aβ40 and Aβ42, accumulate in Alzheimer's disease (AD) senile plaques.
  • While Aβ42 is key in AD pathogenesis, Aβ40's abundance suggests a role in disease progression.
  • Oligomeric amyloid-beta species are implicated in neuronal death and cognitive decline, but their specific roles remain unclear.

Purpose of the Study:

  • To investigate the pathological potential of a modified amyloid beta-40 (Aβ40) dimer.
  • To explore the relationship between Aβ40 oligomerization, structure, and neurotoxicity.

Main Methods:

  • Synthesis of an E22P-Aβ40 dimer linked to l,l-2,6-diaminopimeric acid.
  • Analysis of oligomer formation and structure using biophysical techniques.
  • Assessment of neurotoxicity on human neuroblastoma cells.

Main Results:

  • The synthesized E22P-Aβ40 dimer formed stable 6-8-mer oligomers without amyloid fibrils, exhibiting no neurotoxicity.
  • Under different conditions, E22P-Aβ40 generated high molecular weight oligomers that formed fibrils and demonstrated neurotoxicity.
  • These findings suggest that specific Aβ40 dimer structures with parallel β-sheets may not be inherently pathological.

Conclusions:

  • The structural characteristics of Aβ40 oligomers significantly influence their pathological potential.
  • Not all Aβ40 oligomeric species contribute to Alzheimer's disease pathogenesis.
  • Further research into Aβ structure-toxicity relationships is crucial for understanding AD.